论文部分内容阅读
目的:探讨磷酸氯喹治疗新型冠状病毒肺炎（COVID-19）的安全性，为临床安全用药提供参考。方法:对2020年2月至3月在深圳市第三人民医院住院并使用磷酸氯喹进行治疗的COVID-19患者治疗期间的不良事件（AE）实施主动监测，对AE与磷酸氯喹的因果关系进行评价。结果:共有33例患者纳入研究，男性16例，女性17例，年龄（43±13）岁；COVID-19临床分型为轻型者26例（78.8%），普通型者7例（21.2%）；7例患者（21.2%）有基础疾病，6例为高血压病，1例为甲状腺功能减退。磷酸氯喹疗程为（8±3）d。33例患者在治疗期间有24例（72.7%）发生很可能或可能与磷酸氯喹有关的AE共28例次。AE的临床表现包括肝功能异常（8/33，24.2%）、胃肠道反应（8/33，24.2%）、神经精神系统反应（8/33，24.2%）、心血管系统反应（5/33，15.2%）、眼和视力异常（2/33，6.1%）及皮肤损伤（1/33，3.0%）。AE的严重程度均为1级或2级，所有患者在停药或经对症处理后症状好转，实验室检查恢复正常。结论:磷酸氯喹治疗COVID-19的不良反应较轻，但仍需要加强监测。“,”Objective:To explore the safety of chloroquine phosphate treatment in patients with novel coronavirus pneumonia (COVID-19) and provide references for clinical safety medication.Methods:Active monitoring for adverse events (AE) was carried out in the Third People′s Hospital of Shenzhen from February to March 2020 during the treatment with chloroquine phosphate in patients with COVID-19. The causal relationship between AE and chloroquine phosphate was evaluated.Results:A total of 33 patients were entered in the study, including 16 males and 17 females, aged (43±13) years. The clinical types of COVID-19 in 26 patients (78.8%) were mild, in 7 patients (21.2%) were common. There were 7 patients (21.2%) with basic diseases, including 6 with hypertension and 1 with hypothyroidism. The treatment course of chloroquine phosphate was (8±3) days. During the treatment, a total of 28 cases of AE in 24 (72.7%) of the 33 patients which were probably or possibly related to chloroquine phosphate were detected. The clinical manifestations of AE included abnormal liver function (8/33, 24.2%), gastrointestinal reactions (8/33, 24.2%), neuropsychiatric system reactions (8/33, 24.2%), cardiovascular system reactions (5/33, 15.2%), eye and vision abnormality (2/33, 6.1%), and skin injury (1/33, 3.0%). The severity of AE was grade 1 or grade 2. After drug withdrawal or symptomatic treatments, all the patients′ symptoms were improved and the laboratory tests results returned to normal.Conclusion:The adverse effects of chloroquine phosphate in the treatment of patients with COVID-19 are mild, but it is still necessary to strengthen the monitoring.